Clinical Course in Chronic Subdural Hematoma Patients Aged 18–49 Compared to Patients 50 Years and Above: A Multicenter Study and Meta-Analysis

Jiri Bartek Jr.1,2,3,*, Kristin Sjåvik4†, Sanjay Dhawan5, Lisa M. Sagberg6,7, Helena Kristiansson1, Fredrik Ståhl8, Petter Förander1, Clark C. Chen5 and Asgeir S. Jakola6,9,10

1Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden, 2Department of Clinical Neuroscience and Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, 4Department of Neurosurgery, University Hospital of North Norway, Tromsø, Norway, 5Department of Neurosurgery, University of Minnesota, Minneapolis, MN, United States, 6Department of Neurosurgery, St. Olavs University Hospital, Trondheim, Norway, 7Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway, 8Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden, 9Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden, 10Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska Academy, Gothenburg, Sweden

Objective: Chronic Subdural Hematoma (cSDH) is primarily a disease of elderly, and is rare in patients <50 years, and this may in part be related to the increased brain atrophy from 50 years of age. This fact may also influence clinical presentation and outcome. The aim of this study was to study the clinical course with emphasis on clinical presentation of cSDH patients in the young (<50 years).

Methods: A retrospective review of a population-based cohort of 1,252 patients operated for cSDH from three Scandinavian neurosurgical centers was conducted. The primary end-point was difference in clinical presentation between the patients <50 y/o and the remaining patients (≥50 y/o group). The secondary end-points were differences in perioperative morbidity, recurrence and mortality between the two groups. In addition, a meta-analysis was performed comparing clinical patterns of cSDH in the two age groups.

Results: Fifty-two patients (4.2%) were younger than 50 years. Younger patients were more likely to present with headache (86.5% vs. 37.9%, p < 0.001) and vomiting (25% vs. 5.2%, p < 0.001) than the patients ≥50 y/o, while the ≥50 y/o group more often presented with limb weakness (17.3% vs. 44.8%, p < 0.001), speech impairment (5.8% vs. 26.2%, p = 0.001) and gait disturbance or falls (23.1% vs. 50.7%, p < 0.001). There was no difference between the two groups in recurrence, overall complication rate and mortality within 90 days. Our meta-analysis confirmed that younger patients are more likely to present with headache (p = 0.015) while the hemispheric symptoms are more likely in patients ≥50 y/o (p < 0.001).
INTRODUCTION

Chronic subdural hematoma (cSDH) is a diagnosis with increasing prevalence among the older. Nevertheless, cSDH is also seen in younger patients (previously defined as <50 years in literature), although less commonly (1–5). While cSDH in the young is often associated with predisposing condition i.e., arachnoid cysts, coagulation disorders, or ventriculo-peritoneal shunts, even cSDH without predisposing condition has been reported, often in connection with head trauma (6, 7). Correct interpretation of clinical presentation is important for timely diagnosis. Nevertheless, the reports from literature on the clinical presentation of younger patients with cSDH are varied and often conflicting (1–5). Also, even though surgical evacuation is the main treatment modality in cSDH patients, little is known as to the recurrence rates, morbidity and mortality of young patients with surgically treated cSDH. A large-scale, population-based multicenter study is warranted to benchmark the clinical course and outcome of younger patients with cSDH.

In this population-based multicenter study of adult patients with cSDH, we assessed the clinical course and outcome in patients <50 years, and compared results to the group of patients ≥50 y/o.

MATERIALS AND METHODS

Eligible Study Patients

Adult patients (≥18 years old) with a cSDH (defined as hypodensity, hyperdensity, and/or combined hypo- and hyperdensity on computed tomography (CT) treated with burr hole evacuation between January 1, 2005 and December 31, 2010 at the departments of Neurosurgery at St. Olavs University Hospital (Trondheim, Norway), Karolinska University Hospital (Stockholm, Sweden) and the University Hospital of North Norway (Tromsø, Norway) were included. Patients operated intracranially within the past 6 months, patients with ventriculo-peritoneal shunts, with cSDH in relation to arachnoidal cysts were excluded. The Nordic health care system with regional referral practice to neurosurgical centers ensures a representative population-based study, with data gathering for this database done by experienced medical staff. As reported previously, there was no differences between regions in the age and sex adjusted incidence rates (p = 0.096, data not shown) (8).

Conclusion: Younger patients with cSDH present more often with signs of increased intracranial pressure, while those ≥50 y/o more often present with hemispheric symptoms. No difference exists between the two groups in terms of recurrence, morbidity, and short-term mortality. Knowledge of variations in clinical presentation is important for correct and timely diagnosis in younger cSDH patients.

Keywords: chronic subdural hematoma, young, neurosurgery, symptoms, clinical course, morbidity, mortality, meta-analysis

Treatment Characteristics

Diagnosis was ascertained by a computed tomography (CT) and/or magnetic resonance imaging (MRI) in all patients. Anticonvulsants were not routinely administered unless the patient has experienced convulsions. cSDH evacuation was performed according to local practice (8). At all centers taking part in the study, surgery was offered to all patients with symptomatic cSDH as first-line treatment regardless of age.

Study and Outcome Variables

According to previously calculated (9) age-adjusted incidence rates for the different age groups the incidence is very low, 0.6/100.000 among patients 18–49 y/o, while this rise to 7.1/100.000 (50–66 y/o) and up to 59.5/100.000 (80–89 y/o). This information together with knowledge of brain atrophy increasing after 50 years of age (10), and that this age group of 18–49 years old was <5% of our population-based cohort argued for a “younger group” aged 18–49 years old.

Data collection for this manuscript was done by experienced medical staff using the electronic patient records at each center, with data quality confirmed by the principal investigator based upon quality control. End of follow-up was 01.01.2012, thus all patients were followed at least 1 year or until death. Recurrence was defined as same-sided chronic subdural hematoma within 6 months following index surgery. Patient characteristics included data on the pre-operative status including comorbidity and residential situation (home without assistance, home care and institution) (11), Radiology characteristics included hematoma location (right, left, and bilateral), density (hypodense, mixed, isodens, and hyperdens) and midline shift. Further, the radiology was reviewed to ensure that no apparent bleeding source (such as an AVM, fistula, tumor etc.) was present in any of the included patients, nor did any included patient have any structural abnormalities. Also, upon review, the younger group did not have any signs of early atrophy. Adverse events within 30 days were classified according to Landriel Ibanez et al. (12), with severe morbidity classified as Landriel grade III. Mortality was assessed at 1 and 3 months. Recurrent cSDH was defined as any same-sided cSDH treatment within 6 months of index surgery.

Overall recurrence and survival were illustrated by Kaplan-Meier analysis and compared with log-rank test. According to protocol, we evaluated recurrence up to 6 months after surgery as done by others (13), since most recurrences occur early and a longer time-span would increase chance of including de novo cases rather than treatment failures. We had 6 months follow-up
on all patients, however in the analysis of overall survival patients were censored at end of follow up if still alive.

**Meta-Analysis**

Systematic review of literature and meta-analysis was performed to determine if differences exist between <50 y/o and ≥50 y/o patients with subdural hematoma in terms of sex, medical history, presenting symptoms, imaging findings, and complication rates. The cut off age was chosen as 50 years for the meta-analysis except for 4 studies with 40 and 45 years as the cut off age (these were included due to their large cohort size).

The meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines (14). A comprehensive PubMed database search was conducted on May 17th, 2018 using the term (subdural hematoma OR SDH) [Title/Abstract] AND (young* OR elderly* OR adult* OR age groups* OR comparison) [Title/Abstract] (Figure 1).

Articles were included if they: (1) were written in English (or an English translation was available), (2) involved human subjects, (3) were fully published peer-reviewed clinical articles, (4) had at least an abstract available, (5) included a comparison of the younger and older patients with cSDH. Case reports, articles related to basic sciences and other operative techniques in stereotaxy; editorials, commentaries, or conference proceedings were excluded. The literature search was not restricted by the date of publication of the articles. In the meta-analysis, hemispheric symptoms were defined as occurrence of sensory or motor deficit, gait disturbance, speech impairment, mental status change, or seizure. Bleeding tendency was considered to be present if the patient was on anti-platelets or anticoagulation therapy, or with a hematologic disorder or liver disease.

**Statistical Analysis**

SPSS version 24.0 (SPSS, Inc., Chicago, IL, USA) was used for analysis, while the meta-analysis was performed using Comprehensive Meta-Analysis software (Version 3.3070, BioStat, Englewood, NJ, USA). Significance was defined as $P < 0.05$, with no adjustments for multiple comparisons. Continuous variables were analyzed using an unpaired two-tailed $t$-test for normally distributed data. Continuous data with skewed distribution were analyzed with the Mann-Whitney $U$-test. Discrete variables were compared using a Chi-square analysis. The meta-analysis was done by pooling results using a random-effects model. Heterogeneity was categorized as low (25–50%), moderate (50–75%), or high (>75%) (15). Publication bias was evaluated using funnel plots, Egger's regression intercept test, and Duval and Tweedie's trim and fill test (16, 17).

**RESULTS**

One thousand two hundred and fifty two patients operated for cSDH were included. We identified 52 patients (4.2%) with...
primary operations for cSDH evacuation in younger patients aged 49 or less (<50 y/o group). The median age in the respective age groups was 40.9 years in the younger group and 75.4 years in the ≥50 y/o group. The median follow-up time (from surgery until end of follow-up) was 42 months in the younger group and 43 months in the ≥50 y/o group.

Younger patients presented more often with headache (86.5% vs. 37.9%, p < 0.001) and vomiting (25.0% vs. 5.2%, p < 0.001), while the patients ≥50 y/o more often presented with limb weakness (17.3% vs. 44.8%, p < 0.001), speech impairment (5.8% vs. 26.2%, p = 0.001) and gait disturbance or falls (23.1% vs. 50.7%, p < 0.001). No difference between groups was seen with respect to cognitive deterioration, acute confusion, drowsiness or coma, seizures, incontinence and/or visual disturbances. See Table 1 for further details.

Compared to the patients ≥50 y/o, the younger patients had less comorbidities (13.5% vs. 34.6%, p = 0.002), were more independent (p < 0.001) and used less anti-platelets (1.9% vs. 28.1%, p < 0.001) and anti-coagulants (5.8% vs. 17.9%, p = 0.02). Pre-operatively, younger patients had on average a smaller hematoma diameter (18 mm vs. 22 mm, p < 0.001), but midline shift was similar. Younger patients were less often operated with local anesthesia and sedation only (84.6% vs. 94.7%, p = 0.002). See Table 2 for further details.

Outcome
Younger patients had more often a clinical (p = 0.002) and/or radiological (p = 0.005) follow-up after surgery. No difference between groups was seen with respect to recurrence (Figure 4) and complications (Table 3). There was a difference in overall survival between groups (p = 0.002, Figure 5). See also Table 3 for further details.

Meta-Analysis Results With <50 Years as Cut-Off
Fourteen studies including the current study were included in the meta-analysis (4, 18–32). Date of publication ranged from 1979 to 2018. Among a total of 2,440 patients, 282 were classified as younger (<50 y/o). Cohort size, male sex, headache, nausea/vomiting, hemispheric symptoms, papilledema, recurrence, history of trauma, and hematoma thickness are summarized for each group (Supplementary Tables 1, 2). Younger patients are significantly more likely to present with headache (p = 0.015) while the hemispheric symptoms are more likely to be experienced by the patients ≥50 y/o (p < 0.001, Figure 2).

No statistical differences were found concerning hematoma thickness (p = 0.08) or nausea/vomiting (p = 0.11), gender (p = 0.74), recurrence rate (p = 0.51), history of trauma (p = 0.77), and bleeding tendency (p = 0.55) between age groups (Figures 2, 3). No publication bias was noted among the included studies for any variable as is evident from the gross symmetry of the funnel plots (Supplementary Figures S1, S2).

### Table 1: Clinical presentation in patients with cSDH <50 y/o vs. ≥50 y/o.

| Characteristics         | 18–49 y/o n = 52 (%) | ≥50 y/o n = 1,200 (%) | p-value |
|-------------------------|----------------------|-----------------------|---------|
| Limb weakness           | 9 (17.3)             | 538 (44.8%)           | <0.001  |
| Headache                | 45 (86.5%)           | 455 (37.9%)           | <0.001  |
| Speech impairment       | 3 (5.8)              | 314 (26.2%)           | 0.001   |
| Gait disturbance or falls| 12 (23.1)            | 608 (50.7%)           | <0.001  |
| Cognitive deterioration | 8 (15.4)             | 283 (23.6%)           | 0.17    |
| Acute confusion         | 6 (11.5)             | 251 (20.9%)           | 0.10    |
| Drowsiness or coma      | 6 (11.5)             | 197 (16.4%)           | 0.38    |
| Seizure                 | 1 (1.9)              | 37 (3.1%)             | 0.63    |
| Incontinence            | 0                    | 55 (4.6%)             | 0.11    |
| Visual disturbances     | 1 (1.9)              | 20 (1.7%)             | 0.89    |
| Vomiting                | 13 (25.0)            | 62 (5.2%)             | <0.001  |

**Table 2**: Baseline and per-operative characteristics in patients with cSDH <50 y/o vs. ≥50 y/o.

| Characteristics                  | 18–49 y/o n = 52 (%) | ≥50 y/o n = 1,200 (%) | p-value |
|----------------------------------|----------------------|-----------------------|---------|
| Median age, years (SD)           | 40.9 (6.7)           | 75.4 (10.4)           | <0.001  |
| Mean follow-up in months (SD)    | 42 (21)              | 43 (19)               | 0.65    |
| Sex male                         | 37 (71.2)            | 835 (69.6)            | 0.81    |
| GCS* > 1                         | 7 (13.5)             | 415 (34.6)            | 0.002   |
| Bilateral surgery (missing, n = 3) | 5 (9.6)             | 212 (18.2)           | 0.11    |
| Hypodense or mixed density       | 33 (66.0)            | 830 (74.6)            | 0.18    |
| Missing 89                       | 18.0 (6.0)           | 22.0 (6.2)            | <0.001  |
| Largest diameter mean mm (SD)    | 8.5 (5.1)            | 7.7 (4.7)             | 0.24    |
| Midline shift, mean mm (SD)      |                      |                      |         |
| GCS** in categories              |                      |                      | 0.38    |
| 13–15                            | 49 (94.2)            | 1061 (89.8)           |         |
| 9–12                             | 3 (5.8)              | 82 (6.9)              |         |
| 3–8                              | 0                    | 39 (3.3)              |         |
| Missing 18                       | 1 (1.9)              | 337 (28.1)            | <0.001  |
| Antiplatelet drugs               |                      |                      |         |
| Missing 2                        | 3 (5.8)              | 215 (17.9)            | 0.02    |
| Anticoagulants                   |                      |                      |         |
| Missing 2                        |                      |                      |         |
| Home w/o care                    | 51 (98.1)            | 880 (73.3)            | <0.001  |
| Home with support                | 1 (1.9)              | 205 (17.1)            |         |
| Institution                      | 0                    | 110 (9.4)             |         |
| Surgical procedure               |                      |                      | <0.001  |
| Passive drain                    | 13 (25.0)            | 323 (26.9)            |         |
| Continuous                       | 5 (9.6)              | 141 (11.8)            |         |
| Subgaleal/subperiostal           | 30 (57.7)            | 729 (60.8)            |         |
| Burrhole without drainage        | 4 (7.7)              | 7 (0.6)               |         |
| Local anesthesia + sedation      | 44 (84.6)            | 1,133 (94.7)          | 0.002   |

*Charlson Comorbidity Index; **Glasgow Coma Scale.
DISCUSSION

This multicenter, population-based study is to the best of our knowledge the largest cohort study in literature on young patients with cSDH, demonstrating that younger patients (<50 y/o) with cSDH present more often with signs of increased intracranial pressure, while patients ≥50 y/o more often present with neurological deficits. Patients <50 y/o have similar rates of recurrence and perioperative morbidity as compared to patients ≥50 y/o. The diversity in clinical presentation depending on patient age is important for correct and timely diagnosis of cSDH. And although a head scan should be considered in cases of persisting signs of headache, nausea and vomiting without neurological deficits in young adults, one needs to keep in mind the incidence of post-concussion syndrome which is 50% at 1 month and 15% at 1 year when assessing patients (33). Further, to the best of our knowledge, we have conducted the first meta-analysis to compare the clinical pattern in patients <50 y/o vs. ≥50 y/o with cSDH.

Baseline and Per-Operative Characteristics

The baseline characteristics between groups did not differ significantly except from the younger having less comorbidities, being more independent and using less of both anti-platelets and anticoagulants. Despite increased use of antiplatelet and anticoagulant drugs in the patients ≥50 y/o, the meta-analysis suggests no significant increase in bleeding tendency in this age group.

Between 50 and 80 years of age, it has been shown that the weight of the brain decreases approximately 200 grams (34). Further, the space between the brain and skull increases from 6 to 11% of the total intracranial space (35). As such, this offers greater space for a hematoma to expand without necessarily increasing the intracranial pressure (2, 4). We and others have observed larger on average hematoma diameter in the patients ≥50 y/o, which is logical from a biological point of view. This is even substantiated by the fact that there were 7.7% of younger patients operated with burr hole only (compared to 0.6% of patients ≥50 y/o patients), since the lack of subdural “space” and early...
brain realignment prevented any drainage being placed. Finally, probably due to the increased risk of adverse events associated to the use of general anesthesia in older patients, local anesthesia + sedation was the preferred method of per-operative sedation (36).

**Clinical Presentation**

The clinical presentation was dominated by signs/symptoms of raised intracranial pressure in the patients <50 y/o; headache and vomiting—both which has been previously reported by others as being the cardinal symptoms in young patients with cSDH (1, 2, 4, 5). This is likely explained by a mass effect without significant age-related atrophy, in line with findings that age up to 49 years had no significant influence on the weight of the human brain (10). Thus, symptoms arrive earlier (smaller hematomas) and apparently before neurological deficits occur in most cases, but the midline shift is similar between age groups.

Our findings are consistent with the existing literature as evident from the meta-analysis results, with the younger population more likely to present with headache, and nausea and vomiting, in contrast to the hemispheric symptoms which are more commonly a finding in patients ≥50 y/o.

**Outcome**

Similar recurrence rate for cSDH was observed in our study consistent with the meta-analysis results. In the present study, clinical and radiological post-operative controls were less frequently undertaken in the patients ≥50 y/o—which is in line with our belief that there might be a higher threshold to diagnose patients ≥50 y/o, and especially the very old may more often be institutionalized to begin with.

The frequency of adverse events correlated to surgical treatment of cSDH in the younger has been reported to be similar when compared to older or even those extremely old (4, 9), although adverse events are generally seldom reported at all in series concerning the young cSDH patients (2). In our material, although non-significant, patients ≥50 y/o had a higher frequency of overall complications (9.0% vs. 3.8%) than the patients <50 y/o. This becomes even more evident when only
Bartek et al. Chronic Subdural Hematoma in the Young

FIGURE 4 | Kaplan-Meier plot illustrating recurrence ($p = 0.64$).

TABLE 3 | Outcome in patients with cSDH $<$50 y/o vs. $\geq$50 y/o.

| Characteristics                  | 18–49 y/o | $\geq$50 y/o | $p$-value |
|----------------------------------|----------|--------------|-----------|
| CT control planned               | 26 (50.0) | 364 (31.4)   | 0.005     |
| Missing                          | 41       | 264 (31.4)   |           |
| Clinical control planned at hospital | 36 (69.2) | 546 (47.2)   | 0.002     |
| Missing                          | 42       | 364 (31.4)   |           |
| Recurrence                       | 8 (15.4)  | 161 (13.4)   | 0.68      |
| Overall complication             | 2 (3.8)   | 108 (9.0)    | 0.20      |
| Complication Landriel grade $\geq$3 | 0         | 37 (3.1)     | 0.20      |
| Mortality 30 days                | 0         | 42 (3.5)     | 0.17      |
| Missing                          | 2         | 264 (31.4)   |           |
| Mortality 90 days                | 1 (1.9)   | 76 (6.3)     | 0.19      |

looking at serious adverse events (defined as Landriel grade $\geq$3) which only occurred among the patients $\geq$50 y/o ($n = 37$, 3.1%).

With respect to mortality, it has been reported in literature that cSDH in the old may reveal and/or exacerbate underlying medical condition leading to poor outcome, a so-called “sentinel health event” as described by Miranda et al. (37), which also demonstrated a lower functional status in older patients at discharge, than when they were first admitted. Nevertheless, we found no significant difference in 30 and 90 days mortality between groups, although a difference in overall survival was noted ($p = 0.002$).

Strengths and Limitations

Limitations and potential sources of bias associated with retrospective data analysis are present in the current study. Another limitation is the lack of etiological data as well as long-term follow-up data and functional status postoperatively. Nevertheless, our series represents the largest consecutive series of patients $<$50 y/o operated for cSDH, with a population-based setting making it less at risk of selection bias. Also, our study only takes into account recurrences leading to reoperation—which might have introduced bias in terms of detection and selection.

Further, we have conducted the first meta-analysis comparing clinical profile of patients $<$50 y/o vs. patients $\geq$50 y/o with cSDH. The pooled sample size was considerable, with 2,440 patients from 14 studies, which increased the power of our study. No obvious publication bias were detected which added to the reliability of this analysis. Presence of a significant heterogeneity between the included studies is one of the limitations of our study.

CONCLUSION

In this multicenter, population-based study of patients with cSDH, supplemented by a meta-analysis based on current literature, we demonstrate a significant difference in clinical presentation of patients $<$50 y/o vs. patients $\geq$50 y/o with cSDH. Also, we demonstrate comparable morbidity-, recurrence- and peri-operative mortality rates between groups. It seems reasonable to conclude that attention to clinical presentation is crucial for timely diagnosis of patients with cSDH.

ETHICS STATEMENT

An approval from the Stockholm regional ethical review board in Sweden (EPN 2013/591-31/1) and The Regional Committee for Medical and Health Research Ethics in Central Norway (2011/2050) was obtained prior to study initiation.
AUTHOR CONTRIBUTIONS

JB, KS, and AJ designed the study. JB, KS, SD, LS, HK, FS, PF, CC, and AJ performed the data gathering, analysis, and interpretation. JB, KS, and SD drafted the manuscript. JB, KS, SD, LS, HK, FS, and PF critically revised the manuscript under the supervision of CC and AJ.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2019.00311/full#supplementary-material

REFERENCES

1. Bosma JJ, Miles JB, Shaw MD. Spontaneous chronic and subacute subdural haematoma in young adults. Acta Neurochir. (2000) 142:1307–10. doi: 10.1007/s007010070030
2. Foehlholm R, Waltimo O. Epidemiology of chronic subdural haematoma. Acta Neurochir. (1975) 32:247–50. doi: 10.1007/BF01405457
3. Hou K, Li CG, Zhang Y, Zhu BX. The surgical treatment of three young chronic subdural hematoma patients with different causes. J Korean Neurosurg Soc. (2014) 55:218–21. doi: 10.3340/jkns.2014.55.4.218
4. Liliang PC, Tsai YD, Liang CL, Lee TC, Chen HJ. Chronic subdural haematoma in young and extremely adults: a comparative study of two age groups. Injury. (2002) 33:345–8. doi: 10.1016/S0020-1383(02)00020-7
5. Misiori P, Maraglino C, Tarantino R, Salvati M, Calderaro G, Santoro A, et al. Chronic subdural hematomas in patients aged under 50. Clin Neurol Neurosurg. (2000) 102:199–202. doi: 10.1016/S0303-8467(00)00102-5
6. Albanese A, Tuttolomondo A, Anile C, Sabatino G, Pompucci A, Pintor A, et al. Spontaneous chronic subdural hematomas in young adults with a deficiency in coagulation factor XIII. Report of three cases. J Neurosurg. (2005) 102:1130–2. doi: 10.3171/jns.2005.102.6.1130
7. Mori K, Yamamoto T, Horinaka N, Maeda M. Arachnoid cyst is a risk factor for chronic subdural hematoma in juveniles: twelve cases of chronic subdural hematoma associated with arachnoid cyst. J Neurol Neurosurg Psychiatry. (2002) 19:1017–27. doi: 10.1098/rspp.2002.0319
8. Sjävik K, Bartek J Jr, Sagberg LM, Henriksen ML, Gulati S, Stahl FL, et al. Assessment of drainage techniques for evacuation of chronic subdural hematoma: a consecutive population-based comparative cohort study. J Neurosurg. (2017) 1–7. doi: 10.3171/2016.12.JNS161173
9. Bartek J Jr, Sjävik K, Stahl E, Kristiansson H, Solheim O, Gulati S, et al. Surgery for chronic subdural hematoma in nonagenarians: a Scandinavian population-based multicenter study. Acta Neurol Scand. (2017) 136:516–20. doi: 10.1111/ane.12764
10. Kivela E. On the weight of Finnish brains. Ann Acad Sci Fenn. (1957) 66
11. Carlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. (1987) 40:373–83. doi: 10.1016/0021-9681(87)90171-8
12. Landriel Ibanez FA, Hem S, Ajler P, Vecchi E, Ciarallo C, Baccamelli M, et al. A new classification of complications in neurosurgery. World Neurosurg. (2011) 75:709–15. doi: 10.1016/j.wneu.2010.11.010
13. Santarius T, Kirkpatrick PJ, Ganesan D, Chia HL, Jailoh I, Smielewski P, et al. Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial. Lancet. (2009) 374:1067–73. doi: 10.1016/S0140-6736(09)61115-6
14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. (2009) 339:b2700. doi: 10.1136/bmj.b2700
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557
16. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. (2000) 56:455–63. doi: 10.1111/j.0006-341x.2000.00455.x
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. (1997) 315:629–34. doi: 10.1136/bmj.315.7109.629
18. Aspgegren OP, Astrand R, Lundgren MI, Romner B. Anti-icoagulation therapy a risk factor for the development of chronic subdural hematoma. Clin Neurol Neurosurg. (2013) 115:981–4. doi: 10.1016/j.clineuro.2012.10.008
19. Mortensen, H, Heiskanen O, Waltimo O. Chronic subdural hematoma in adults. Influence of patient’s age on symptoms, signs, and thickness of hematoma. J Neurol. (1975) 42:43–6. doi: 10.1007/bmj.371975.42.1.0043
20. Kalliperumal C, Khalil A, Fenton E, Okafu K, Kaar G, O’Sullivan M, et al. A prospective randomised study to compare the utility and outcomes of subdural and subperiostial drains for the treatment of chronic subdural hematoma. Acta Neurochir. (2012) 154:2083–8. doi: 10.1007/s00701-012-1483-1
21. Koste M, Waltimo O, Heiskanen O. Chronic bilateral subdural hematoma in adults. Acta Neurochir. (1979) 48:231–6. doi: 10.1007/BF02056971
22. Kotwica Z, Brzezinski J. Clinical pattern of chronic subdural hematoma. Neurochirurgia. (1991) 34:148–50. doi: 10.1055/s-1994-2007026
23. Kwak YS, Hwang SK, Park SH, Park YJ. Chronic subdural hematoma associated with the middle fossa arachnoid cyst: pathogenesis and review of its management. Childs Nerv Syst. (2003) 29:77–82. doi: 10.1007/s00381-002-1896-4
24. Luxon LM, Harrison MJ. Chronic subdural hematoma. Q J Med. (1979) 48:43–53.
25. Park SH, Lee SH, Park J, Hwang JH, Hwang SK, Hamm JS. Chronic subdural hematoma preceded by traumatic subdural hygroma. J Clin Neurosci. (2008) 15:868–72. doi: 10.1016/j.jocn.2007.08.003
26. Potdar NKS, Bhavadasan K. Age comparative study of chronic subdural hematoma and its outcome.- A retrospective study. Int J Med Sci Clin Invent. (2017) 4. doi: 10.18535/ijmsci/v4i6.11
27. Ramachandran R, Hegde T. Chronic subdural hematomas—causes of morbidity and mortality. Surg Neurol. (2007) 67:367–72. doi: 10.1016/j.surneu.2006.07.022
28. Takizawa K, Sorimachi T, Honda Y, Ishizaka H, Baba T, Osada T, et al. Chronic subdural hematomas associated with arachnoid cysts: significance in young patients with chronic subdural hematoma. Neurol Med Chir. (2013) 55:427–4. doi: 10.2176/nmc.2013-0016
29. Thotakura AK, Marabathina NR. Nonsurgical treatment of chronic subdural hematoma with steroids. World Neurosurg. (2015) 84:1968–72. doi: 10.1016/j.wneu.2015.08.044
30. Tokmak M, Iplikcioglu AC, Bek S, Golduman CA, Erdal M. The role of exudation in chronic subdural hematomas. J Neurosurg. (2007) 107:290–5. doi: 10.3171/jns/07/08/0290
31. Wang D, Li T, Tian Y, Wang S, Jin C, Wei H, et al. Effects of atorvastatin on chronic subdural hematoma: a preliminary report from three medical centers. J Neuroscl. (2014) 336:237–42. doi: 10.1016/j.jns.2013.11.005
32. Won YD, Yi HJ, Chun HJ, Cho H, Bak KH. Chronic subdural hematoma in young adults: an age comparison study. *Korean J Neurotrauma*. (2013) 9:6–11. doi: 10.13004/kjnt.2013.9.1.6
33. Bazarian JJ, McClung J, Shah MN, Cheng YT, Flesher W, Kraus J. Mild traumatic brain injury in the United States, 1998–2000. *Brain Inj*. (2005) 19:85–91. doi: 10.1080/02699050410001720158
34. Boyd E, Ma TM. *Pathology of the Nervous System*. New York, NY: McGraw Hill Book Co. (1968). p. 120–37.
35. McMenemey WH. *Greenfield’s Neuropathology*. Baltimore, MA: Williams and Wilkins (1963). p. 520–80.
36. Kim SO, Jung SI, Won YS, Choi CS, Yang JY. A comparative study of local versus general anesthesia for chronic subdural hematoma in elderly patients over 60 years. *Korean J Neurotrauma*. (2013) 9:47–51. doi: 10.13004/kjnt.2013.9.2.47
37. Miranda LB, Braxton E, Hobbs J, Quigley MR. Chronic subdural hematoma in the elderly: not a benign disease. *J Neurosurg*. (2011) 114:72–6. doi: 10.3171/2010.8.JNS10298

**Conflict of Interest Statement**: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Bartek, Sjävik, Dhawan, Kristiansson, Ståhl, Förander, Chen and Jakola. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.